At the Suman Paul laboratory, we are focused on developing new antibodies and cell therapies for cancer treatment. Our team of researchers are dedicated to identifying novel targets, mechanisms for cancer therapy and developing innovative solutions to improve patient outcomes. We work closely with basic science researchers and clinicians to accelerate the translation of our discoveries into clinical practice.

The Johns Hopkins comprehensive Subependymoma and Ependymoma Research Center divideS its efforts into three areas: basic science, translational research and clinical practice. Each division works separately but shares findings and resources openly with each other and our collaborators. The goal of our united efforts is to optimize current treatments to affect the care received by patients with subependymomas and ependymomas. Also, our clinical, translational and basic science teams work to develop novel therapies to improve and extend the lives of those with these rare tumors.

The Michaelis Laboratory's research goal is to dissect fundamental cellular processes relevant to human health and disease, using yeast and mammalian cell biology, biochemistry and high-throughput genomic approaches. Our team studies the cell biology of lamin A and its role in the premature aging disease Hutchinson-Gilford progeria syndrome (HGPS). Other research focuses on the core cellular machinery involved in recognition of misfolded proteins. Understanding cellular protein quality control machinery will ultimately help researchers devise treatments for protein misfolding diseases in which degradation is too efficient or not enough.

The Susan Tuddenham Lab studies sexually transmitted diseases, in particular ocular syphilis.

Researchers in the Suzanne Jan de Beur Lab are interested in bone and mineral metabolism, endocrinology and osteoporosis. In addition, we focus on hormonal regulators of phosphate homeostasis, parathyroid hormone signaling and the molecular basis of hypophosphatemic disorders.

Our lab currently focuses on three areas of immunotherapy research: gaining a deeper knowledge of the biological underpinnings of human autoimmune response; discovering biomarkers that will help us identify which patients and tumor types are most likely to respond to various immune therapies; and developing immune-based treatment combinations that could deliver a more powerful anti-tumor response than monotherapies.

The research in the Svetlana Lutsenko Laboratory is focused on the molecular mechanisms that regulate copper concentration in normal and diseased human cells. To understand the molecular mechanisms of copper homeostasis in normal and diseased human cells, we utilize a multidisciplinary approach involving biochemical and biophysical studies of molecules involved in copper transport, cell biological studies of copper signaling, and analysis of copper-induced pathologies using Wilson's disease gene knock-out mice.

The SIP Lab studies the mechanisms of normal and disordered swallowing. The team conducts research in the areas of swallowing rehabilitation after stroke, effects of aging on swallowing and measurement of swallowing physiology.

The Sydney Dy Lab has conducted extensive research on quality of care, patient safety and decision-making, with a focus on patients with cancer and other serious and terminal diseases. Our team seeks to improve health systems and services to optimize the use of technology and medication, particularly in end-of-life health care policy. Our research approach includes primary and quantitative data collection, quality measurement improvement, systematic literature reviews and analysis of secondary database.

The Systems Biology Lab applies methods of multiscale modeling to problems of cancer and cardiovascular disease, and examines the systems biology of angiogenesis, breast cancer and peripheral artery disease (PAD). Using coordinated computational and experimental approaches, the lab studies the mechanisms of breast cancer tumor growth and metastasis to find ways to inhibit those processes. We use bioinformatics to discover novel agents that affect angiogenesis and perform in vitro and in vivo experiments to test these predictions. In addition we study protein networks that determine processes of angiogenesis, arteriogenesis and inflammation in PAD. The lab also investigates drug repurposing for potential applications as stimulators of therapeutic angiogenesis, examines signal transduction pathways and builds 3D models of angiogenesis. The lab has discovered over a hundred novel anti-angiogenic peptides, and has undertaken in vitro and in vivo studies testing their activity under different conditions. We have investigated structure-activity relationship (SAR) doing point mutations and amino acid substitutions and constructed biomimetic peptides derived from their endogenous progenitors. They have demonstrated the efficacy of selected peptides in mouse models of breast, lung and brain cancers, and in age-related macular degeneration.